Lepu Medical Technology Co (300003) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2026 was ¥3.21 billion, down 4.61% year-over-year; net profit attributable to shareholders was ¥499 million, down 27.71% year-over-year.

• Excluding a one-time convertible bond redemption expense, adjusted net profit fell 14.79% year-over-year.

• The company maintained a strong position in cardiovascular devices, expanded innovation in neuroregulation and brain-machine interface, and advanced its internationalization strategy.

• Cash dividend of ¥1.6275 per 10 shares proposed, totaling ¥300 million.

Financial highlights

• Operating income: ¥3.21 billion, down 4.61% year-over-year.

• Net profit attributable to shareholders: ¥499 million, down 27.71% year-over-year.

• Adjusted net profit (excluding one-off bond expense): ¥564 million, down 14.79% year-over-year.

• Operating cash flow: ¥633 million, down 0.60% year-over-year.

• Basic and diluted EPS: ¥0.2710, down 27.69% year-over-year.

• R&D investment: ¥604 million, up 13.40% year-over-year.

Outlook and guidance

• The company will continue to focus on innovation, consumer healthcare, and international expansion.

• Plans to accelerate new product development and commercialization, especially in high-value consumables and innovative drugs.

• International business and consumer healthcare expected to be new growth drivers.